FDA Adverse Events Reports (FAERS) Summary for ACCUPRIL

These tables and charts are based on 6,162 total reports for ACCUPRIL (QUINAPRIL HYDROCHLORIDE) received by the FDA Adverse Event Reporting System (FAERS) from 2004 through April 28, 2026.

This FAERS total includes 6,090 pharmaceutical company-submitted and non-U.S. FAERS reports and 72 U.S. consumer or healthcare provider-submitted MedWatch reports. For a separate summary of the 72 U.S. reports filed via the FDA MedWatch voluntary reporting system, view our FDA MedWatch ACCUPRIL summary report. (See notes section below for explanation of FDA’s mandatory and voluntary reporting system.)

Top 20 Adverse Effects Associated with ACCUPRIL (reported in FAERS Database)

	Side Effect	# of FDA Reports
1	HEART ATTACK (MYOCARDIAL INFARCTION)	424
2	NAUSEA	374
3	PAIN	358
4	DRUG INEFFECTIVE	357
5	SHORTNESS OF BREATH	345
6	CONGESTIVE HEART FAILURE	329
7	DIZZINESS	328
8	FATIGUE	322
9	STROKE	311
10	DIARRHEA	281
11	HIGH BLOOD PRESSURE	275
12	HEADACHE	261
13	FALL	256
14	CHEST PAIN	242
15	ANXIETY	240
16	LACK OF STRENGTH AND ENERGY (ASTHENIA)	236
17	KIDNEY FAILURE	213
18	JOINT PAIN	210
19	CORONARY ARTERY DISEASE	209
20	DRUG HYPERSENSITIVITY	209
21	BLOOD GLUCOSE INCREASED	203
22	DEPRESSION	202
23	PAIN IN EXTREMITY	201
24	VOMITING	201
25	WEIGHT DECREASED	199
26	MALAISE	190
27	DIABETES MELLITUS	189
28	COUGH	187
29	SWELLING OF LIMBS	182
30	DEATH	181
31	BLOOD PRESSURE INCREASED	178
32	ANEMIA	165
33	BACK PAIN	161
34	INJURY	160
35	INSOMNIA	151
36	PNEUMONIA	151
37	ATRIAL FIBRILLATION	148
38	LOW BLOOD PRESSURE	143
39	CONSTIPATION	138
40	WEIGHT INCREASED	138
41	RASH	131
42	ITCHING	130
43	BLOOD CHOLESTEROL INCREASED	125
44	FEELING ABNORMAL	122
45	CARDIAC DISORDER	121
46	MUSCLE SPASMS	121
47	CONDITION AGGRAVATED	118
48	DEHYDRATION	115
49	GASTROOESOPHAGEAL REFLUX DISEASE	115
50	MUSCLE PAIN	115
51	URINARY TRACT INFECTION	113
52	FEVER	112
53	ABDOMINAL PAIN UPPER	107
54	NUMBNESS	107
55	EMOTIONAL DISTRESS	104
56	ABDOMINAL PAIN	103
57	LOSS OF CONSCIOUSNESS	98
58	RENAL FAILURE ACUTE	97
59	CHRONIC KIDNEY DISEASE	96
60	DECREASED APPETITE	94
61	OSTEOARTHRITIS	94
62	PALPITATIONS	94
63	OFF LABEL USE	92
64	STRESS	92
65	TYPE 2 DIABETES MELLITUS	90
66	CHRONIC OBSTRUCTIVE PULMONARY DISEASE	89
67	EXCESS SWEATING	89
68	CONFUSIONAL STATE	86
69	GAIT DISTURBANCE	86
70	PINS AND NEEDLES	86
71	FAINTING	85
72	VISION BLURRED	84
73	HEART ATTACK	82
74	DROWSINESS	81
75	INDIGESTION	80
76	BRONCHITIS	77
77	HEART RATE INCREASED	77
78	ARTHRITIS	76
79	DRUG INTERACTION	76
80	GASTROINTESTINAL BLEEDING	76
81	HYPERLIPIDAEMIA	76
82	COMMON COLD	74
83	CHEST DISCOMFORT	73
84	HAIR LOSS	72
85	STROKE	72
86	ACUTE KIDNEY INJURY	69
87	ANGINA ATTACK	69
88	JOINT SWELLING	69
89	FEAR	68
90	LOW BLOOD SUGAR	68
91	LOSS OF ALL PLEASURE	67
92	BLOOD PRESSURE DECREASED	67
93	HYPERSENSITIVITY	67
94	UNEVALUABLE EVENT	67
95	CELLULITIS	66
96	FLUSHING	65
97	MUSCULAR WEAKNESS	65
98	BALANCE DISORDER	64
99	NEUROPATHY PERIPHERAL	64
100	SKIN REDNESS	62

Latest Known Outcomes for Reactions Reported for ACCUPRIL

	Latest Known Outcome for Reported Reactions	Number of Cases
1	Unknown Outcome	1481
2	Patient recovered	734
3	Patient has not recovered/symtoms have not resolved	548
4	Patient is recovering/symptoms resolving	219
5	Patient died	159
6	Patient has recovered but has consequent health issues	21

Search all MedWatch and FAERS by keyword:

ACCUPRIL Total Reports

Male	Female	Unknown	Total
2608	3390	164	6,162

Top Countries Reporting

	Country	Number of Reports
1	United States	2008
2	Canada	186
3	Peru	53
4	New Zealand	28
5	Australia	12
6	Puerto Rico	9
7	Belgium	6
8	Venezuela	3
9	Colombia	2
10	EU	2

Outcomes for Reports

Serious: 4247
Not Serious: 1915
Note: A serious outcome means the adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition.

Top Indications

HIGH BLOOD PRESSURE

Top Companies Reporting

Safety-Related FDA Updates

FDA Approval Date: 1991-11-19

ACCUPRIL (QUINAPRIL HYDROCHLORIDE) Rx Drug:
Safety-related Labeling Changes

Have experience (good or bad) with ACCUPRIL? Rate ACCUPRIL at Ask a Patient.

For serious adverse events, report them to the FDA by contacting the drug manufacturer or report directly through the MedWatch voluntary reporting form.

Notes

This report, created by AskaPatient.com, is derived from the cases for ACCUPRIL reported to the United States Food and Drug Administration (FDA) FDA Safety Information and Adverse Event Reporting System (FAERS) and obtained from Open FDA. Data was last updated with reports received through April 28, 2026.

This summary includes ALL reports where the drug is a "primary OR secondary OR suspected interacting" drug. Typically, reports are filed for the most serious type or "event" and do not represent incidental or minor side effects. The majority of these reports are mandatory reports submitted by pharmaceutical companies, who receive complaints from consumers. The reactions, side effects, or "adverse events," represent up to the 20 most frequently occuring events in the database for a drug related to the event. This report also features counts of latest known outcomes associated with reported side effects, but does not provide the specific outcomes for specific adverse events.

Adverse Event Reports are submitted to the FAERS database by pharmaceutical companies (mandatory reporting is required by manufacturers, distributors, or importers). Health care providers such as doctors (voluntary reporting), and patients themselves (voluntary reporting) report to the FDA directly through the MedWatch program. Those MedWatch reports are coded and included in the FAERS database. This report mainly consists of the mandatory reports, because the MedWatch reports are a small percentage (3 - 5%) of total reports. Link to the MedWatch summary report at the top of the page for a summary of the directly reported (voluntary) adverse events for this drug.The number of reports included here might differ somewhat from the number of reports in the downloadable quarterly FAERS reports and in the online FAERS dashboard, due to lags in reporting, drug name differences, duplicates, and other factors. Open FDA states that it only includes the most recent version of a case report. It also adds the disclaimer: "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated."

FDA uses the "MedDRA" classification system to describe reported adverse reactions. MedDRA is a standardized medical terminology that facilitates sharing of regulatory information internationally. In some cases, "patient friendly" terms for the layman designated by MedDRA have been substituted for medical jargon. Please contact us with questions or comments about this report.